Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 163

1.

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[d]thiazol-5-ylamino)-6-(tert-butylsulfonyl)quinazolin-7-yl)oxy)ethyl Dihydrogen Phosphate, for the Treatment of Inflammatory Diseases.

Haile PA, Casillas LN, Votta BJ, Wang GZ, Charnley AK, Dong X, Bury MJ, Romano JJ, Mehlmann JF, King BW, Erhard KF, Hanning CR, Lipshutz DB, Desai BM, Capriotti CA, Schaeffer MC, Berger SB, Mahajan MK, Reilly MA, Nagilla R, Rivera EJ, Sun HH, Kenna JK, Beal AM, Ouellette MT, Kelly M, Stemp G, Convery MA, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Marquis RW.

J Med Chem. 2019 Jul 25;62(14):6482-6494. doi: 10.1021/acs.jmedchem.9b00575. Epub 2019 Jul 2.

PMID:
31265286
2.

Identification of a RIP1 Kinase Inhibitor Clinical Candidate (GSK3145095) for the Treatment of Pancreatic Cancer.

Harris PA, Marinis JM, Lich JD, Berger SB, Chirala A, Cox JA, Eidam PM, Finger JN, Gough PJ, Jeong JU, Kang J, Kasparcova V, Leister LK, Mahajan MK, Miller G, Nagilla R, Ouellette MT, Reilly MA, Rendina AR, Rivera EJ, Sun HH, Thorpe JH, Totoritis RD, Wang W, Wu D, Zhang D, Bertin J, Marquis RW.

ACS Med Chem Lett. 2019 May 9;10(6):857-862. doi: 10.1021/acsmedchemlett.9b00108. eCollection 2019 Jun 13.

3.

Author Correction: Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2019 Jun;570(7761):E53. doi: 10.1038/s41586-019-1265-5.

PMID:
31142845
4.

Discovery and Lead-Optimization of 4,5-Dihydropyrazoles as Mono-Kinase Selective, Orally Bioavailable and Efficacious Inhibitors of Receptor Interacting Protein 1 (RIP1) Kinase.

Harris PA, Faucher N, George N, Eidam PM, King BW, White GV, Anderson NA, Bandyopadhyay D, Beal AM, Beneton V, Berger SB, Campobasso N, Campos S, Capriotti CA, Cox JA, Daugan A, Donche F, Fouchet MH, Finger JN, Geddes B, Gough PJ, Grondin P, Hoffman BL, Hoffman SJ, Hutchinson SE, Jeong JU, Jigorel E, Lamoureux P, Leister LK, Lich JD, Mahajan MK, Meslamani J, Mosley JE, Nagilla R, Nassau PM, Ng SL, Ouellette MT, Pasikanti KK, Potvain F, Reilly MA, Rivera EJ, Sautet S, Schaeffer MC, Sehon CA, Sun H, Thorpe JH, Totoritis RD, Ward P, Wellaway N, Wisnoski DD, Woolven JM, Bertin J, Marquis RW.

J Med Chem. 2019 May 23;62(10):5096-5110. doi: 10.1021/acs.jmedchem.9b00318. Epub 2019 May 2.

PMID:
31013427
5.

RIPK1 and Caspase-8 Ensure Chromosome Stability Independently of Their Role in Cell Death and Inflammation.

Liccardi G, Ramos Garcia L, Tenev T, Annibaldi A, Legrand AJ, Robertson D, Feltham R, Anderton H, Darding M, Peltzer N, Dannappel M, Schünke H, Fava LL, Haschka MD, Glatter T, Nesvizhskii A, Schmidt A, Harris PA, Bertin J, Gough PJ, Villunger A, Silke J, Pasparakis M, Bianchi K, Meier P.

Mol Cell. 2019 Feb 7;73(3):413-428.e7. doi: 10.1016/j.molcel.2018.11.010. Epub 2018 Dec 28.

6.

10/10 Organisation française de l’aide aux victimes.

Mons O, Sadowski I, Bertin J, Lefort H.

Soins. 2018 Dec;63(831):59-61. doi: 10.1016/j.soin.2018.10.018. French. No abstract available.

PMID:
30551758
Free Article
7.

RIP1 Kinase Drives Macrophage-Mediated Adaptive Immune Tolerance in Pancreatic Cancer.

Wang W, Marinis JM, Beal AM, Savadkar S, Wu Y, Khan M, Taunk PS, Wu N, Su W, Wu J, Ahsan A, Kurz E, Chen T, Yaboh I, Li F, Gutierrez J, Diskin B, Hundeyin M, Reilly M, Lich JD, Harris PA, Mahajan MK, Thorpe JH, Nassau P, Mosley JE, Leinwand J, Kochen Rossi JA, Mishra A, Aykut B, Glacken M, Ochi A, Verma N, Kim JI, Vasudevaraja V, Adeegbe D, Almonte C, Bagdatlioglu E, Cohen DJ, Wong KK, Bertin J, Miller G.

Cancer Cell. 2018 Nov 12;34(5):757-774.e7. doi: 10.1016/j.ccell.2018.10.006.

PMID:
30423296
8.

Design of amidobenzimidazole STING receptor agonists with systemic activity.

Ramanjulu JM, Pesiridis GS, Yang J, Concha N, Singhaus R, Zhang SY, Tran JL, Moore P, Lehmann S, Eberl HC, Muelbaier M, Schneck JL, Clemens J, Adam M, Mehlmann J, Romano J, Morales A, Kang J, Leister L, Graybill TL, Charnley AK, Ye G, Nevins N, Behnia K, Wolf AI, Kasparcova V, Nurse K, Wang L, Puhl AC, Li Y, Klein M, Hopson CB, Guss J, Bantscheff M, Bergamini G, Reilly MA, Lian Y, Duffy KJ, Adams J, Foley KP, Gough PJ, Marquis RW, Smothers J, Hoos A, Bertin J.

Nature. 2018 Dec;564(7736):439-443. doi: 10.1038/s41586-018-0705-y. Epub 2018 Nov 7. Erratum in: Nature. 2019 Jun;570(7761):E53.

PMID:
30405246
9.

Necroptosis inhibition as a therapy for Niemann-Pick disease, type C1: Inhibition of RIP kinases and combination therapy with 2-hydroxypropyl-β-cyclodextrin.

Cougnoux A, Clifford S, Salman A, Ng SL, Bertin J, Porter FD.

Mol Genet Metab. 2018 Dec;125(4):345-350. doi: 10.1016/j.ymgme.2018.10.009. Epub 2018 Oct 30.

PMID:
30392741
10.

Pathogen blockade of TAK1 triggers caspase-8-dependent cleavage of gasdermin D and cell death.

Orning P, Weng D, Starheim K, Ratner D, Best Z, Lee B, Brooks A, Xia S, Wu H, Kelliher MA, Berger SB, Gough PJ, Bertin J, Proulx MM, Goguen JD, Kayagaki N, Fitzgerald KA, Lien E.

Science. 2018 Nov 30;362(6418):1064-1069. doi: 10.1126/science.aau2818. Epub 2018 Oct 25.

11.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW.

ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044. doi: 10.1021/acsmedchemlett.8b00344. eCollection 2018 Oct 11.

PMID:
30344914
12.

LUBAC prevents lethal dermatitis by inhibiting cell death induced by TNF, TRAIL and CD95L.

Taraborrelli L, Peltzer N, Montinaro A, Kupka S, Rieser E, Hartwig T, Sarr A, Darding M, Draber P, Haas TL, Akarca A, Marafioti T, Pasparakis M, Bertin J, Gough PJ, Bouillet P, Strasser A, Leverkus M, Silke J, Walczak H.

Nat Commun. 2018 Sep 25;9(1):3910. doi: 10.1038/s41467-018-06155-8.

13.

Elevated A20 promotes TNF-induced and RIPK1-dependent intestinal epithelial cell death.

Garcia-Carbonell R, Wong J, Kim JY, Close LA, Boland BS, Wong TL, Harris PA, Ho SB, Das S, Ernst PB, Sasik R, Sandborn WJ, Bertin J, Gough PJ, Chang JT, Kelliher M, Boone D, Guma M, Karin M.

Proc Natl Acad Sci U S A. 2018 Sep 25;115(39):E9192-E9200. doi: 10.1073/pnas.1810584115. Epub 2018 Sep 12.

14.

Use of RIP1 Kinase Small-Molecule Inhibitors in Studying Necroptosis.

Beal AM, Bertin J, Reilly MA.

Methods Mol Biol. 2018;1857:109-124. doi: 10.1007/978-1-4939-8754-2_11.

PMID:
30136235
15.

Caspase-8 Collaborates with Caspase-11 to Drive Tissue Damage and Execution of Endotoxic Shock.

Mandal P, Feng Y, Lyons JD, Berger SB, Otani S, DeLaney A, Tharp GK, Maner-Smith K, Burd EM, Schaeffer M, Hoffman S, Capriotti C, Roback L, Young CB, Liang Z, Ortlund EA, DiPaolo NC, Bosinger S, Bertin J, Gough PJ, Brodsky IE, Coopersmith CM, Shayakhmetov DM, Mocarski ES.

Immunity. 2018 Jul 17;49(1):42-55.e6. doi: 10.1016/j.immuni.2018.06.011.

16.

MLKL Requires the Inositol Phosphate Code to Execute Necroptosis.

Dovey CM, Diep J, Clarke BP, Hale AT, McNamara DE, Guo H, Brown NW Jr, Cao JY, Grace CR, Gough PJ, Bertin J, Dixon SJ, Fiedler D, Mocarski ES, Kaiser WJ, Moldoveanu T, York JD, Carette JE.

Mol Cell. 2018 Jun 7;70(5):936-948.e7. doi: 10.1016/j.molcel.2018.05.010. Epub 2018 Jun 7.

17.

LUBAC is essential for embryogenesis by preventing cell death and enabling haematopoiesis.

Peltzer N, Darding M, Montinaro A, Draber P, Draberova H, Kupka S, Rieser E, Fisher A, Hutchinson C, Taraborrelli L, Hartwig T, Lafont E, Haas TL, Shimizu Y, Böiers C, Sarr A, Rickard J, Alvarez-Diaz S, Ashworth MT, Beal A, Enver T, Bertin J, Kaiser W, Strasser A, Silke J, Bouillet P, Walczak H.

Nature. 2018 May;557(7703):112-117. doi: 10.1038/s41586-018-0064-8. Epub 2018 Apr 25.

18.

S100A12 and S100A8/9 proteins are biomarkers of articular disease activity in Blau syndrome.

Wang L, Rosé CD, Foley KP, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Fernández-Martín J, Guly C, Hachulla E, Harjacek M, Mackensen F, Merino R, Modesto C, Naranjo Hernández A, Pajot C, Ramanan AV, Thatayatikom A, Thomée C, Vastert S, Votta BJ, Bertin J, Wouters CH.

Rheumatology (Oxford). 2018 Apr 7. doi: 10.1093/rheumatology/key090. [Epub ahead of print]

PMID:
29635517
19.

Ubiquitin-Mediated Regulation of RIPK1 Kinase Activity Independent of IKK and MK2.

Annibaldi A, Wicky John S, Vanden Berghe T, Swatek KN, Ruan J, Liccardi G, Bianchi K, Elliott PR, Choi SM, Van Coillie S, Bertin J, Wu H, Komander D, Vandenabeele P, Silke J, Meier P.

Mol Cell. 2018 Feb 15;69(4):566-580.e5. doi: 10.1016/j.molcel.2018.01.027.

20.

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers.

Weisel K, Scott NE, Tompson DJ, Votta BJ, Madhavan S, Povey K, Wolstenholme A, Simeoni M, Rudo T, Richards-Peterson L, Sahota T, Wang JG, Lich J, Finger J, Verticelli A, Reilly M, Gough PJ, Harris PA, Bertin J, Wang ML.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.365.

21.

Identification of an antibody-based immunoassay for measuring direct target binding of RIPK1 inhibitors in cells and tissues.

Finger JN, Brusq JM, Campobasso N, Cook MN, Deutsch J, Haag H, Harris PA, Jenkins EL, Joglekar D, Lich JD, Maguire S, Nagilla R, Rivera EJ, Sun H, Votta BJ, Bertin J, Gough PJ.

Pharmacol Res Perspect. 2017 Dec;5(6). doi: 10.1002/prp2.377.

22.

Autophagy protein ATG16L1 prevents necroptosis in the intestinal epithelium.

Matsuzawa-Ishimoto Y, Shono Y, Gomez LE, Hubbard-Lucey VM, Cammer M, Neil J, Dewan MZ, Lieberman SR, Lazrak A, Marinis JM, Beal A, Harris PA, Bertin J, Liu C, Ding Y, van den Brink MRM, Cadwell K.

J Exp Med. 2017 Dec 4;214(12):3687-3705. doi: 10.1084/jem.20170558. Epub 2017 Oct 31.

23.

t-BuOOH induces ferroptosis in human and murine cell lines.

Wenz C, Faust D, Linz B, Turmann C, Nikolova T, Bertin J, Gough P, Wipf P, Schröder AS, Krautwald S, Dietrich C.

Arch Toxicol. 2018 Feb;92(2):759-775. doi: 10.1007/s00204-017-2066-y. Epub 2017 Oct 3.

PMID:
28975372
24.

Blau Syndrome-Associated Uveitis: Preliminary Results From an International Prospective Interventional Case Series.

Sarens IL, Casteels I, Anton J, Bader-Meunier B, Brissaud P, Chédeville G, Cimaz R, Dick AD, Espada G, Fernandez-Martin J, Guly CM, Hachulla E, Harjacek M, Khubchandani R, Mackensen F, Merino R, Modesto C, Naranjo A, Oliveira-Knupp S, Özen S, Pajot C, Ramanan AV, Russo R, Susic G, Thatayatikom A, Thomée C, Vastert S, Bertin J, Arostegui JI, Rose CD, Wouters CH.

Am J Ophthalmol. 2018 Mar;187:158-166. doi: 10.1016/j.ajo.2017.08.017. Epub 2017 Sep 6.

PMID:
28887115
25.

RIPK1-dependent apoptosis bypasses pathogen blockade of innate signaling to promote immune defense.

Peterson LW, Philip NH, DeLaney A, Wynosky-Dolfi MA, Asklof K, Gray F, Choa R, Bjanes E, Buza EL, Hu B, Dillon CP, Green DR, Berger SB, Gough PJ, Bertin J, Brodsky IE.

J Exp Med. 2017 Nov 6;214(11):3171-3182. doi: 10.1084/jem.20170347. Epub 2017 Aug 30.

26.

Genetic Inhibition of Receptor Interacting Protein Kinase-1 Reduces Cell Death and Improves Functional Outcome After Intracerebral Hemorrhage in Mice.

Lule S, Wu L, McAllister LM, Edmiston WJ 3rd, Chung JY, Levy E, Zheng Y, Gough PJ, Bertin J, Degterev A, Lo EH, Whalen MJ.

Stroke. 2017 Sep;48(9):2549-2556. doi: 10.1161/STROKEAHA.117.017702. Epub 2017 Aug 1.

27.

Kinase Activities of RIPK1 and RIPK3 Can Direct IFN-β Synthesis Induced by Lipopolysaccharide.

Saleh D, Najjar M, Zelic M, Shah S, Nogusa S, Polykratis A, Paczosa MK, Gough PJ, Bertin J, Whalen M, Fitzgerald KA, Slavov N, Pasparakis M, Balachandran S, Kelliher M, Mecsas J, Degterev A.

J Immunol. 2017 Jun 1;198(11):4435-4447. doi: 10.4049/jimmunol.1601717. Epub 2017 May 1.

28.

Distinct Kinase-Independent Role of RIPK3 in CD11c+ Mononuclear Phagocytes in Cytokine-Induced Tissue Repair.

Moriwaki K, Balaji S, Bertin J, Gough PJ, Chan FK.

Cell Rep. 2017 Mar 7;18(10):2441-2451. doi: 10.1016/j.celrep.2017.02.015.

29.

Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis.

Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, Milner TA, Jonas EA, Ratan RR.

Stroke. 2017 Apr;48(4):1033-1043. doi: 10.1161/STROKEAHA.116.015609. Epub 2017 Mar 1.

30.

Discovery of a First-in-Class Receptor Interacting Protein 1 (RIP1) Kinase Specific Clinical Candidate (GSK2982772) for the Treatment of Inflammatory Diseases.

Harris PA, Berger SB, Jeong JU, Nagilla R, Bandyopadhyay D, Campobasso N, Capriotti CA, Cox JA, Dare L, Dong X, Eidam PM, Finger JN, Hoffman SJ, Kang J, Kasparcova V, King BW, Lehr R, Lan Y, Leister LK, Lich JD, MacDonald TT, Miller NA, Ouellette MT, Pao CS, Rahman A, Reilly MA, Rendina AR, Rivera EJ, Schaeffer MC, Sehon CA, Singhaus RR, Sun HH, Swift BA, Totoritis RD, Vossenkämper A, Ward P, Wisnoski DD, Zhang D, Marquis RW, Gough PJ, Bertin J.

J Med Chem. 2017 Feb 23;60(4):1247-1261. doi: 10.1021/acs.jmedchem.6b01751. Epub 2017 Feb 10.

PMID:
28151659
31.

RIPK1/RIPK3 promotes vascular permeability to allow tumor cell extravasation independent of its necroptotic function.

Hänggi K, Vasilikos L, Valls AF, Yerbes R, Knop J, Spilgies LM, Rieck K, Misra T, Bertin J, Gough PJ, Schmidt T, de Almodòvar CR, Wong WW.

Cell Death Dis. 2017 Feb 2;8(2):e2588. doi: 10.1038/cddis.2017.20.

32.

RIPK1 protects from TNF-α-mediated liver damage during hepatitis.

Filliol A, Piquet-Pellorce C, Le Seyec J, Farooq M, Genet V, Lucas-Clerc C, Bertin J, Gough PJ, Dimanche-Boitrel MT, Vandenabeele P, Bertrand MJ, Samson M.

Cell Death Dis. 2016 Nov 10;7(11):e2462. doi: 10.1038/cddis.2016.362.

33.

Cell-Extrinsic TNF Collaborates with TRIF Signaling To Promote Yersinia-Induced Apoptosis.

Peterson LW, Philip NH, Dillon CP, Bertin J, Gough PJ, Green DR, Brodsky IE.

J Immunol. 2016 Nov 15;197(10):4110-4117. Epub 2016 Oct 12.

34.

Kinase-independent function of RIP1, critical for mature T-cell survival and proliferation.

Dowling JP, Cai Y, Bertin J, Gough PJ, Zhang J.

Cell Death Dis. 2016 Sep 29;7(9):e2379. doi: 10.1038/cddis.2016.307.

35.

MALT1 Protease Activation Triggers Acute Disruption of Endothelial Barrier Integrity via CYLD Cleavage.

Klei LR, Hu D, Panek R, Alfano DN, Bridwell RE, Bailey KM, Oravecz-Wilson KI, Concel VJ, Hess EM, Van Beek M, Delekta PC, Gu S, Watkins SC, Ting AT, Gough PJ, Foley KP, Bertin J, McAllister-Lucas LM, Lucas PC.

Cell Rep. 2016 Sep 27;17(1):221-232. doi: 10.1016/j.celrep.2016.08.080.

36.

Life after death: RIP1 and RIP3 move beyond necroptosis.

Berger SB, Bertin J, Gough PJ.

Cell Death Discov. 2016 Jul 18;2:16056. doi: 10.1038/cddiscovery.2016.56. eCollection 2016. No abstract available.

37.

RIPK1 and RIPK3 Kinases Promote Cell-Death-Independent Inflammation by Toll-like Receptor 4.

Najjar M, Saleh D, Zelic M, Nogusa S, Shah S, Tai A, Finger JN, Polykratis A, Gough PJ, Bertin J, Whalen M, Pasparakis M, Balachandran S, Kelliher M, Poltorak A, Degterev A.

Immunity. 2016 Jul 19;45(1):46-59. doi: 10.1016/j.immuni.2016.06.007. Epub 2016 Jul 5.

38.

RIPK3 Activates Parallel Pathways of MLKL-Driven Necroptosis and FADD-Mediated Apoptosis to Protect against Influenza A Virus.

Nogusa S, Thapa RJ, Dillon CP, Liedmann S, Oguin TH 3rd, Ingram JP, Rodriguez DA, Kosoff R, Sharma S, Sturm O, Verbist K, Gough PJ, Bertin J, Hartmann BM, Sealfon SC, Kaiser WJ, Mocarski ES, López CB, Thomas PG, Oberst A, Green DR, Balachandran S.

Cell Host Microbe. 2016 Jul 13;20(1):13-24. doi: 10.1016/j.chom.2016.05.011. Epub 2016 Jun 16.

39.

K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.

Shutinoski B, Alturki NA, Rijal D, Bertin J, Gough PJ, Schlossmacher MG, Sad S.

Cell Death Differ. 2016 Oct;23(10):1628-37. doi: 10.1038/cdd.2016.51. Epub 2016 Jun 3.

40.

RIPK1 and PGAM5 Control Leishmania Replication through Distinct Mechanisms.

Farias Luz N, Balaji S, Okuda K, Barreto AS, Bertin J, Gough PJ, Gazzinelli R, Almeida RP, Bozza MT, Borges VM, Chan FK.

J Immunol. 2016 Jun 15;196(12):5056-63. doi: 10.4049/jimmunol.1502492. Epub 2016 May 16.

41.

The Identification and Pharmacological Characterization of 6-(tert-Butylsulfonyl)-N-(5-fluoro-1H-indazol-3-yl)quinolin-4-amine (GSK583), a Highly Potent and Selective Inhibitor of RIP2 Kinase.

Haile PA, Votta BJ, Marquis RW, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Lakdawala AS, Convery MA, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, Beal AM, Finger JN, Cook MN, King BW, Ouellette MT, Totoritis RD, Pierdomenico M, Negroni A, Stronati L, Cucchiara S, Ziółkowski B, Vossenkämper A, MacDonald TT, Gough PJ, Bertin J, Casillas LN.

J Med Chem. 2016 May 26;59(10):4867-80. doi: 10.1021/acs.jmedchem.6b00211. Epub 2016 May 4.

PMID:
27109867
42.

Corrigendum to "A sensitive, simple and robust LC-MS/MS method for the simultaneous quantification of seven androgen- and estrogen-related steroids in postmenopausal serum" [J. Steroid Biochem. Mol. Biol. 144 (2014) 523-534].

Ke Y, Bertin J, Gonthier R, Simard JN, Labrie F.

J Steroid Biochem Mol Biol. 2016 Apr;158:231. doi: 10.1016/j.jsbmb.2015.12.021. Epub 2015 Dec 23. No abstract available.

PMID:
29106850
43.

DNA-Encoded Library Screening Identifies Benzo[b][1,4]oxazepin-4-ones as Highly Potent and Monoselective Receptor Interacting Protein 1 Kinase Inhibitors.

Harris PA, King BW, Bandyopadhyay D, Berger SB, Campobasso N, Capriotti CA, Cox JA, Dare L, Dong X, Finger JN, Grady LC, Hoffman SJ, Jeong JU, Kang J, Kasparcova V, Lakdawala AS, Lehr R, McNulty DE, Nagilla R, Ouellette MT, Pao CS, Rendina AR, Schaeffer MC, Summerfield JD, Swift BA, Totoritis RD, Ward P, Zhang A, Zhang D, Marquis RW, Bertin J, Gough PJ.

J Med Chem. 2016 Mar 10;59(5):2163-78. doi: 10.1021/acs.jmedchem.5b01898. Epub 2016 Feb 23.

PMID:
26854747
44.

The Mitochondrial Phosphatase PGAM5 Is Dispensable for Necroptosis but Promotes Inflammasome Activation in Macrophages.

Moriwaki K, Farias Luz N, Balaji S, De Rosa MJ, O'Donnell CL, Gough PJ, Bertin J, Welsh RM, Chan FK.

J Immunol. 2016 Jan 1;196(1):407-15. doi: 10.4049/jimmunol.1501662. Epub 2015 Nov 18.

45.

Crystal structures of human RIP2 kinase catalytic domain complexed with ATP-competitive inhibitors: Foundations for understanding inhibitor selectivity.

Charnley AK, Convery MA, Lakdawala Shah A, Jones E, Hardwicke P, Bridges A, Ouellette M, Totoritis R, Schwartz B, King BW, Wisnoski DD, Kang J, Eidam PM, Votta BJ, Gough PJ, Marquis RW, Bertin J, Casillas L.

Bioorg Med Chem. 2015 Nov 1;23(21):7000-6. doi: 10.1016/j.bmc.2015.09.038. Epub 2015 Sep 25.

PMID:
26455654
46.

Drilling into RIP1 biology: what compounds are in your toolkit?

Berger SB, Bertin J, Gough PJ.

Cell Death Dis. 2015 Sep 17;6:e1889. doi: 10.1038/cddis.2015.254. No abstract available.

47.

Absence of RIPK3 predicts necroptosis resistance in malignant melanoma.

Geserick P, Wang J, Schilling R, Horn S, Harris PA, Bertin J, Gough PJ, Feoktistova M, Leverkus M.

Cell Death Dis. 2015 Sep 10;6:e1884. doi: 10.1038/cddis.2015.240.

48.

NF-κB-Independent Role of IKKα/IKKβ in Preventing RIPK1 Kinase-Dependent Apoptotic and Necroptotic Cell Death during TNF Signaling.

Dondelinger Y, Jouan-Lanhouet S, Divert T, Theatre E, Bertin J, Gough PJ, Giansanti P, Heck AJ, Dejardin E, Vandenabeele P, Bertrand MJ.

Mol Cell. 2015 Oct 1;60(1):63-76. doi: 10.1016/j.molcel.2015.07.032. Epub 2015 Sep 3.

49.

High throughput screening identifies ATP-competitive inhibitors of the NLRP1 inflammasome.

Harris PA, Duraiswami C, Fisher DT, Fornwald J, Hoffman SJ, Hofmann G, Jiang M, Lehr R, McCormick PM, Nickels L, Schwartz B, Wu Z, Zhang G, Marquis RW, Bertin J, Gough PJ.

Bioorg Med Chem Lett. 2015 Jul 15;25(14):2739-43. doi: 10.1016/j.bmcl.2015.05.032. Epub 2015 May 19.

PMID:
26022841
50.

Intracellular nicotinamide adenine dinucleotide promotes TNF-induced necroptosis in a sirtuin-dependent manner.

Preyat N, Rossi M, Kers J, Chen L, Bertin J, Gough PJ, Le Moine A, Rongvaux A, Van Gool F, Leo O.

Cell Death Differ. 2016 Jan;23(1):29-40. doi: 10.1038/cdd.2015.60. Epub 2015 May 22.

Supplemental Content

Loading ...
Support Center